XML 68 R57.htm IDEA: XBRL DOCUMENT v3.20.2
Geneos Therapeutics, Inc. - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended 4 Months Ended 9 Months Ended
Jun. 01, 2020
Feb. 28, 2019
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2020
Sep. 30, 2019
Jun. 30, 2020
Mar. 31, 2020
Jan. 31, 2020
Dec. 31, 2019
Noncontrolling Interest [Line Items]                      
Gain on deconsolidation of investment     $ 0 $ 0   $ 4,121,075 $ 0        
Share of net loss in Geneos     1,759,674 $ 0   2,661,431 $ 0        
Investment in equity method investments     $ 957,567   $ 957,567 $ 957,567         $ 0
Geneos Therapeutics, Inc.                      
Noncontrolling Interest [Line Items]                      
Noncontrolling interest, ownership percentage by parent   61.00%             52.00%    
Ownership percentage     47.00%   47.00% 47.00%          
Geneos Therapeutics, Inc.                      
Noncontrolling Interest [Line Items]                      
Payments to acquire additional interest in subsidiaries   $ 1,200,000                  
Stock purchase agreement, commitment of additional investment               $ 800,000   $ 800,000  
Gain on deconsolidation of investment $ 4,121,075                    
Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value 2,400,000                    
Share of net loss in Geneos         $ 2,661,431            
Investment in equity method investments 3,618,998   $ 957,567   957,567 $ 957,567          
Geneos Therapeutics, Inc. | Common stock                      
Noncontrolling Interest [Line Items]                      
Share of net loss in Geneos         819,000            
Investment in equity method investments 819,000   0   0 0          
Geneos Therapeutics, Inc. | Preferred stock                      
Noncontrolling Interest [Line Items]                      
Share of net loss in Geneos         1,800,000            
Investment in equity method investments $ 2,799,998   $ 958,000   $ 958,000 $ 958,000